UK is only European country denying access to “James Bond drug” Erbitux - licensed to kill colorectal cancer
SummaryThe UK is the only country in Europe where patients with metastatic colorectal cancer (mCRC) do not have routine access to Erbitux (cetuximab) a drug with potential to extend survival and even cure some people, it was revealed recently.
The is the only country in where patients with metastatic colorectal cancer (mCRC) do not have routine access to Erbitux (cetuximab) a drug with potential to extend survival and even cure some people, it was revealed recently.
Erbitux approved for treatment of mCRC in countries all over the world, thanks to a British-led study, is able to arrest growth and spread of aggressive tumours and causes cancer cell death. It is approved for use when irinotecan-based chemotherapy has failed. However, trials of Erbitux used early in mCRC alongside several chemotherapies are showing very promising results. Oncologists say it has produced some of the longest survival rates ever seen in mCRC. But a draft appraisal issued June 2006 by NICE, the ’s National Institute For Clinical Excellence, indicated Erbitux and another targeted drug Avastin (bevacuzimab) will be turned down for use in on cost-effectiveness grounds. A final decision will be made in November.
Dr Oliver Kisker, Medical Director of Merck KGaA which makes Erbitux commented: “The is the only country in where the drug has been approved but is not available. In all other European countries, specialists can use the drug and get the cost reimbursed.”
Speaking in Barcelona during the 8th World Congress in Gastrointestinal Cancer, Professor Heinz-Josef Lenz said the trial that led to Erbitux being approved all over the world was led by Professor David Cunningham of the Royal Marsden Hospital in Britain. “Originally the trial had the number 007 but to the British that means James Bond so the trial in known as BOND.” The trial showed Erbitux could overturn a cancer’s power to resist chemotherapy and increase survival. “No other drugs have shown that,” he commented. Since BOND, Erbitux has gone on to produce astounding results in other trials and is now being tested in much larger numbers of patients, he said.Shrinking liver tumours become resectable
A major benefit to emerge is the ability of the drug to shrink liver metastases in around a quarter of patients with advanced disease to the point where they can be resected, ie, surgically removed. Resecting liver secondaries gives patients the best chance of survival, he added. “New combinations of Erbitux and the chemotherapy regimen FOLFOX 4 are expected to translate to a cure for an increasing number of patients. Studies are now examining the role of Erbitux as a first and second-line treatment. But in the , the drug is already used as second-line therapy in specialised centres.”
Also speaking in , Tim Maughan, Professor of Cancer Studies at said: “Where tumours in the liver are resectable, long term follow up shows that half are still alive after five years and almost a third are still alive a decade later.” If tumours in the liver become resectable after Erbitux and chemotherapy, more patients will become survivors, he explained. Three studies show that about 23 or 24 per cent of previously inoperable patients become candidates for surgery. “This is recent data and it opens up the hope of a radically different long-term outcome than we have come to expect. The ball park in mCRC treatment is shifting raipidly. We can get long-term survival benefits without compromising quality of life.”
Professor Maughan is one of few cancer specialists likely to see any benefits of Erbitux in because he practices in . Until the NICE decision is finalised, is permitting its gastro-intestinal cancer specialists to prescribe the drug strictly within its licensed indication for patients who have failed chemotherapy with irinotecan.
Professor Maughan happens also to be leading from , the UK Medical Research Council’s independently-financed massive study of Erbitux and chemotherapy. The COIN study is comparing continuous and intermittent chemotherapy with and without Erbitux in over 2000 patients.
Any discoveries made by the COIN study are unlikely to be enjoyed by the , the country that paid for the study via its sponsorship of the MRC, however.
As Neil Brookes, CEO of the UK colon cancer charity “Bowel Cancer UK” commented: “It is ironic that while the UK has been in the forefront of developing both Erbitux and Avastin, including in clinical trials, it looks as if we will, once again, be at the very back of the queue when it comes to being able to make them available to patients. It is also very hard not to be angry and cynical when NICE appears to be making its decisions on the basis of financial expediency rather than clinical efficacy.”
To see more features by Olwen Glynn Owen follow this link to his first feature article and scroll to the end for a list:
Glivec improves long-term survival prospects for chronic myeloid leukaemia patients